Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Ann Biol Clin (Paris) ; 70(6): 659-65, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-23207810

RESUMO

Production of factor VIII or factor IX inhibitors is a major complication limiting the efficiency of substitutive therapy in haemophiliacs. Moreover, viral infections, the second serious complication of replacement therapy, may be associated to the occurrence of antiphospholipid antibodies which paradoxically lead to thrombosis. We investigated the prevalence of coagulation inhibitors (factor VIII and factor IX inhibitors, antiphospholipid antibodies) in Tunisian haemophiliacs, and we assessed concomitant coagulation factor deficiencies. Thirty-two previously treated haemophiliacs (20 haemophiliacs A; 12 haemophiliacs B) were screened for factor VIII and factor IX inhibitors by APTT mixing study, Bethesda test and modified Nijmegen method, and investigated for the presence of anticardiolipin, anti-ß2 glycoprotein I, lupus anticoagulant and associated coagulation factors deficiencies. The frequency of factor VIII and factor IX inhibitors was low (5%) in contrast to the high prevalence of antiphospholipid antibodies (28.1%). Four and nine patients were positive for anticardiolipin and anti-ß2 glycoprotein I, respectively. No lupus anticoagulant was detected. The prevalence of antiphospholipid antibodies was higher in patients with positive hepatitis C virus infection serology as compared to patients with negative serology (41.6% vs. 20%). Concomitant factor VII and/or factor V deficiency was found in 10 patients. In conclusion, the occurrence of factor VIII and factor IX inhibitors is rare among Tunisian haemophiliacs. The clinical relevance of antiphospholipid antibodies requires further investigations. We emphasize the importance of screening for concomitant deficiencies in haemophiliacs when the clinical presentation is suggestive.


Assuntos
Anticorpos Antifosfolipídeos/sangue , Fator IX/antagonistas & inibidores , Fator VIII/antagonistas & inibidores , Hemofilia A/imunologia , Hemofilia B/imunologia , Adolescente , Adulto , Algoritmos , Anticorpos Anticardiolipina/sangue , Biomarcadores/sangue , Testes de Coagulação Sanguínea , Hemofilia A/sangue , Hemofilia A/diagnóstico , Hemofilia A/terapia , Hemofilia B/sangue , Hemofilia B/diagnóstico , Hemofilia B/terapia , Humanos , Fatores Imunológicos/sangue , Inibidor de Coagulação do Lúpus/sangue , Índice de Gravidade de Doença , Tunísia , beta 2-Glicoproteína I/sangue
2.
Eur J Haematol ; 75(3): 248-51, 2005 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16104882

RESUMO

We determined the frequency of post-transfusion alloimmunisation against platelet and granulocyte antigens in 51 Tunisian polytransfused patients with haematological diseases. Serum samples were analysed by a standard and an antiglobulin-augmented lymphocytotoxicity technique, a granulocyte agglutination test, a granulocyte immunofluorescence test, a platelet immunofluorescence test and the monoclonal antibody-specific immobilisation of platelet antigens assay. No granulocyte-specific antibodies were detected. HLA antibodies were found in 58.8% of patients. Platelet-specific antibodies were detected in four patients and were directed against human platelet antigen (HPA)-5b, HPA-1b and HPA-3a. The three patients with Glanzmann's thrombasthenia developed anti-GPIIb/IIIa antibodies. This study provides immunogenetic information that could improve the management of transfusion therapy in Tunisia.


Assuntos
Plaquetas/imunologia , Granulócitos/imunologia , Autoanticorpos/sangue , Granulócitos/transplante , Antígenos HLA/imunologia , Humanos , Transfusão de Plaquetas , Tunísia
3.
Tunis Med ; 81(4): 226-9, 2003 Apr.
Artigo em Francês | MEDLINE | ID: mdl-12848003

RESUMO

Between 1989 and 1999, 36 cases with primary myelodysplastic syndromes were diagnosed. They were 15 male and 21 females, the median age was 62 years (range: 22 to 90 years). Eighty one per cent of patients were presented symptoms of anemia. Lymphadenopathy, splenomegaly and skin manifestations were noted in 25% of cases. Hemogram showed anemia, leucopenia and thrombocytopenia respectively in 97%, 44% and 55% of cases. Refractory anemia with excess blasts (AREB) is the most frequent FAB subtypes of MDS (17 cases). Cytogenetic study concerned 24 patients. In 13 cases the karyotype was pathological with deletion 5 q in 64% of cases. Seventeen patients have received a chemotherapy. Survival rate to 36 months is 11%. At the time, the only curative treatment is the bone marrow transplantation, which is proposed to young patients with HLA identical donor.


Assuntos
Anemia Refratária com Excesso de Blastos/etiologia , Síndromes Mielodisplásicas/diagnóstico , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Leucopenia/etiologia , Doenças Linfáticas/etiologia , Masculino , Pessoa de Meia-Idade , Síndromes Mielodisplásicas/tratamento farmacológico , Síndromes Mielodisplásicas/genética , Dermatopatias/etiologia , Esplenomegalia/etiologia , Trombocitopenia/etiologia
4.
Tunis Med ; 81(2): 130-3, 2003 Feb.
Artigo em Francês | MEDLINE | ID: mdl-12708180

RESUMO

The authors report an observation of a non-Hodgkinien primitive lymphoma of the thyroid, developed on Hashimoto's thyroiditis. The 61 years old woman was operated on a total thyroidectomy for a multinodular goiter with dysphagia. The non-Hodgkinien high-grade lymphoma infiltrated the perithyroidal tissues. The extension' assessment was negative and the lymphoma was classified stage IE. The treatment was supplemented by 6 cures of standard chemotherapy CEOP. Based on this observation and on a literature' review, we will discuss the clinical and therapeutic characteristics of this thyroid cancer.


Assuntos
Linfoma não Hodgkin , Neoplasias da Glândula Tireoide , Antibióticos Antineoplásicos/administração & dosagem , Antineoplásicos Alquilantes/administração & dosagem , Antineoplásicos Hormonais/administração & dosagem , Antineoplásicos Fitogênicos/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Terapia Combinada , Ciclofosfamida/administração & dosagem , Epirubicina/administração & dosagem , Feminino , Humanos , Linfoma não Hodgkin/diagnóstico , Linfoma não Hodgkin/tratamento farmacológico , Linfoma não Hodgkin/patologia , Linfoma não Hodgkin/cirurgia , Pessoa de Meia-Idade , Prednisona/administração & dosagem , Glândula Tireoide/patologia , Neoplasias da Glândula Tireoide/diagnóstico , Neoplasias da Glândula Tireoide/tratamento farmacológico , Neoplasias da Glândula Tireoide/patologia , Neoplasias da Glândula Tireoide/cirurgia , Tireoidectomia , Tireoidite Autoimune/complicações , Vincristina/administração & dosagem
5.
Tunis Med ; 81(1): 5-10, 2003 Jan.
Artigo em Francês | MEDLINE | ID: mdl-12708185

RESUMO

The incidence of malignancies has increased in conjunction with epidemic of human immunodeficiency virus (HIV) disease and they are currently considered acquired immunodeficiency syndrome (AIDS)-defining conditions. Approximately 40% of all patients with AIDS have developed cancer during the course of HIV infections. Further, as survival has improved in HIV disease, the incidence of these malignancies has increased. The main malignancies noted are Kaposi's sarcoma, non-Hodgkin's lymphoma, Hodgkin's disease, rectal and anal cancer.


Assuntos
Neoplasias do Ânus/patologia , Infecções por HIV/complicações , Doença de Hodgkin/patologia , Linfoma não Hodgkin/patologia , Neoplasias Retais/patologia , Sarcoma de Kaposi/patologia , Neoplasias do Ânus/epidemiologia , Neoplasias do Ânus/etiologia , Doença de Hodgkin/epidemiologia , Doença de Hodgkin/etiologia , Humanos , Incidência , Linfoma não Hodgkin/epidemiologia , Linfoma não Hodgkin/etiologia , Neoplasias Retais/epidemiologia , Neoplasias Retais/etiologia , Sarcoma de Kaposi/epidemiologia , Sarcoma de Kaposi/etiologia
6.
Tunis Med ; 80(4): 199-202, 2002 Apr.
Artigo em Francês | MEDLINE | ID: mdl-12416355

RESUMO

Through a national retrospective study, the authors report the clinical and hematological characteristics of 124 acute lymphoblastic leukemia of the adult diagnosed during 5 years (1993-1997). The national prevalence is of 0.28/100.000 inhabitants/year. The sex-ratio is of 1.3. Sixty six per cent of patients were 16-35 years of age, and only 10% of them were more than 60 years of age. A tumoral syndrome was present at 71% of the cases with peripheral adenopathies in 55%, splenomegaly in 40%, hepatomegaly in 19% and a mediastinal tumor in 18% of the cases. The bone pain were rarely signaled (10%) and neuro-meningeal affection was found in only 3% of cases. There was no testicular lesions. The white blood cells count was less than 30.000/mm3 in 60% whereas an important hyperleucocytosis superior than 100.103/mm3 was observed in 20% of the cases. Anemia and thrombopenia were noted in 94% and 90% of the cases respectively. Acute lymphoblastic leukemia typing by cytological study of Bone marrow according to the Fransh-American-Britain criteria (FAB) had found 43%, 48% and 4% for type 1,2 and 3 respectively. In 5% of the cases the type of the acute lymphoblastic leukemia was not precised (diagnosis based on the Bone biopsy).


Assuntos
Leucemia-Linfoma Linfoblástico de Células Precursoras/epidemiologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/patologia , Adolescente , Adulto , Idade de Início , Idoso , Anemia/etiologia , Biópsia , Feminino , Hepatomegalia/etiologia , Humanos , Contagem de Leucócitos , Masculino , Pessoa de Meia-Idade , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Prevalência , Esplenomegalia/etiologia , Trombocitopenia/etiologia , Tunísia/epidemiologia
7.
Tunis Med ; 80(5): 296-8, 2002 May.
Artigo em Francês | MEDLINE | ID: mdl-12534038
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA